Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.64 |
| ▸ | ACLY | P53396 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.46 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6103451 | 0.92 | SFRP1 (0.77) | SFRP1ACLYAKR1C3ALDH1A1POLB | |
| SCHEMBL4618990 | 0.92 | SFRP1 (0.67) | SFRP1ACLYAKR1C3ALDH1A1POLB | |
| SCHEMBL6103073 | 0.91 | SFRP1 (0.61) | SFRP1ACLYALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL6100257 | 0.90 | SFRP1 (0.64) | SFRP1ACLYAKR1C3ALDH1A1POLB | |
| SCHEMBL4617469 | 0.89 | SFRP1 (0.65) | SFRP1AKR1C3ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL4673213 | 0.88 | SFRP1 (0.71) | SFRP1AKR1C3TBXA2RALDH1A1 | |
| SCHEMBL4616718 | 0.86 | SFRP1 (0.86) | SFRP1TBXA2RALDH1A1POLBL3MBTL1 | |
| SCHEMBL4616578 | 0.85 | SFRP1 (0.67) | SFRP1TBXA2RF2ALDH1A1CNR1 | |
| SCHEMBL6103295 | 0.85 | SFRP1 (0.75) | SFRP1AKR1C3TBXA2RALDH1A1POLB | |
| SCHEMBL6101030 | 0.84 | SFRP1 (0.66) | SFRP1ALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | SFRP1 1/4885ACLY 4729/4885AKR1C3 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.